Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Rong Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematics and Statistics, Beijing Institute of Technology, Beijing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Genomics, Homologous Recombination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIHR Cambridge Biomedical Research Centre, Breast Cancer as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre.
Abstract (Originalsprache)
Homologous recombination deficiency (HRD) leads to genomic instability, and patients with HRD can benefit from HRD‐targeting therapies. Previous studies have primarily focused on identifying HRD biomarkers using data from a single technology. Here we integrated features from different genomic data types, including total copy number (CN), allele‐specific copy number (ASCN) and single nucleotide variants (SNV). Using a semi‐supervised method, we developed HRD classifiers from 1404 breast tumours across two datasets based on their BRCA1/2 status, demonstrating improved HRD identification when aggregating different data types. Notably, HRD‐positive tumours in ER‐negative disease showed improved survival post‐adjuvant chemotherapy, while HRD status strongly correlated with neoadjuvant treatment response. Furthermore, our analysis of cell lines highlighted a sensitivity to PARP inhibitors, particularly rucaparib, among predicted HRD‐positive lines. Exploring somatic mutations outside BRCA1/2 , we confirmed variants in several genes associated with HRD. Our method for HRD classification can adapt to different data types or resolutions and can be used in various scenarios to help refine patient selection for HRD‐targeting therapies that might lead to better clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Mathematics and Statistics, Beijing Institute of Technology, Beijing, China.
- MRC Biostatistics Unit, University of Cambridge, UK.
- Cancer Research UK Cambridge Institute, University of Cambridge, UK.
- Department of Pathology, University of Cambridge, UK.
- Cancer Research Malaysia, Subang Jaya, Malaysia.
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
ORCID-Profile: Rong Zhu, Richard Moulange, Carlos Caldas, Oscar M Rueda
Förderung
- Wellcome Trust
- NIHR Cambridge Biomedical Research Centre
- Breast Cancer as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre
- Medical Research Council
Zitieren
APA
Zhu, R., Eason, K., Chin, S. F., Edwards, P. A. W., Manzano Garcia, R., Moulange, R., Pan, J. W., Teo, S. H., Mukherjee, S., Callari, M., Caldas, C., Sammut, S. J., & Rueda, O. M. (2025). Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data. Molecular Oncology. https://doi.org/10.1002/1878-0261.70041
Vancouver
Zhu R, Eason K, Chin SF, Edwards PAW, Manzano Garcia R, Moulange R, et al. Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data. Molecular Oncology. 2025. doi:10.1002/1878-0261.70041
BibTeX
@article{Zhu2025,
author = {Zhu, Rong and Eason, Katherine and Chin, Suet-Feung and Edwards, Paul A W and Manzano Garcia, Raquel and Moulange, Richard and Pan, Jia Wern and Teo, Soo Hwang and Mukherjee, Sach and Callari, Maurizio and Caldas, Carlos and Sammut, Stephen-John and Rueda, Oscar M},
title = {Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70041}
}
EUVIMED